Compare Cytokinetics Inc (CYTK) vs iShares MSCI China ETF (MCHI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs iShares MSCI China ETF — how do they compare? Cytokinetics Inc trades at $62.75 (market cap $8.62B), while iShares MSCI China ETF trades at $52.47 (market cap $5.94B). The key difference: Cytokinetics Inc is the larger of the two by market cap, and Cytokinetics Inc is trading nearer its 52-week high, iShares MSCI China ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and iShares MSCI China ETF for 63 Days on average.
| CYTK | MCHI | |
|---|---|---|
Market Cap | $8.62B | $5.94B |
Volume | 2,594,626 | 1,575,471 |
Sector | Health | Broad Market / Factor |
52-Week High | $87.26 | $65.59 |
52-Week Low | $54.76 | $50.48 |
Typical Hold Time | 19 Days | 63 Days |
Enterprise Value | $8.72B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $62.48, up 2.23% today, but faces bearish technical signals with 18 sell indicators versus 4 buy signals. The company shows strong revenue growth potential with recent positive Phase 3 trial results for aficamten in non-obstructive HCM, though it operates at significant losses with a -1,321% net income margin. Cash flow remains heavily dependent on financing activities, with operating cash flow negative at -$555 million in 2026.
Wall Street maintains strong bullish sentiment with 97% buy ratings and a $112.60 consensus price target, representing 80% upside potential. Key risks include continued cash burn, competitive pressure from Bristol Myers Squibb's Camzyos, and the need for successful commercialization of pipeline drugs. The stock's valuation appears stretched at 114x sales given current financial performance.
MCHI trades at $52.45, up 1.57% with a bearish technical outlook as moving averages signal strong selling pressure. The ETF faces headwinds from China's economic challenges including industrial overcapacity and weak domestic consumption. Recent news highlights mixed signals with corporate profits surging 26% in Q2 2026 while exports face global pushback. Institutional activity shows conflicting positions with Empowered Funds acquiring shares while Acima Private Wealth reduced holdings.
The outlook remains cautious given China's macroeconomic pressures and trade tensions. Investment opportunity exists in the significant discount to historical valuations, but risks include potential export controls, protectionism threats, and ongoing economic rebalancing challenges that could pressure Chinese equities.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About iShares MSCI China ETF
MCHI is an ETF that seeks to track the investment results of the MSCI China Index. It provides broad exposure to the Chinese equity market, primarily focusing on large and mid-cap companies listed in Hong Kong and Shanghai. MCHI serves as a core holding for investors looking to gain diversified exposure to the performance and growth potential of the companies within the People's Republic of China.
Read more on MCHI →
